Byondis

Join Ivo Grgic, our Senior Director Business Development and Licensing, and Steven Bartz, our Business Development and Licensing Advisor, at BIO International Convention next week! Grounded in more than 20 years of #AntibodyDrugConjugate expertise, #Byondis is evolving the field by engineering #ADCs to tackle the cancers that current therapies cannot reach. Our novel payload platforms, advanced masking technology and optimized linker and conjugation strategies provide broad #partnering flexibility through co-development, licensing and strategic #collaboration. If you’ll be in San Diego and would like to learn more about Byondis’ approach, please reach out via the BIO partnering platform or email BD@Byondis.com. Learn more about Byondis: https://byondis.com/   #BIOInternational #LifeSciences #Pharma

We are excited to announce that Steven Bartz, Ph.D., has joined Byondis as our Strategic Business Development and Licensing Advisor.   With deep expertise in advancing innovative therapeutics and technology platforms, Steven brings over 20 years of biopharma leadership spanning R&D and business development. His strategic counsel will be invaluable as we expand our partnerships and advance our proprietary ADC platforms to deliver differentiated oncology therapeutics for patients with solid tumors.   Steven most recently served as Head of Oncology Search and Evaluation at Pfizer, where he led the identification and execution of strategic partnering opportunities for Pfizer Oncology. Prior to this, he was VP of Licensing at Seagen, where his team executed multiple high-impact partnerships supporting its pipeline and ADC capabilities.   Welcome to Byondis, Steven!   #Byondis #BusinessDevelopment #ADC #AntibodyDrugConjugate #Oncology #Biopharma #MakeHopeReal

We are proud to announce the formation of our Scientific Advisory Board, bringing together internationally recognized experts in antibody-drug conjugate (#ADC) science, therapeutic antibody engineering, and oncology clinical development.   Their strategic and scientific counsel will be instrumental as we advance our proprietary ADC technology platforms and develop differentiated oncology therapeutics for patients with solid tumors.   Welcoming our SAB Members: Dr. John Lambert, Ph.D.: Pioneer in ADC science with a central role in developing technologies behind Kadcyla® and mirvetuximab soravtansine. Former Chief Scientific Officer at ImmunoGen with 120+ peer-reviewed publications.   Dr. Anthony Tolcher, M.D.: Renowned early-phase clinical investigator and principal investigator on first-in-human studies for multiple FDA-approved therapies. Founder and CEO of NEXT Oncology.   Dr.Kapil Dhingra, M.D.: Extensive ADC and targeted therapeutics expertise. Former VP and Head of Oncology Clinical Development at Hoffmann-La Roche. Advisor to multiple oncology companies in transformative acquisitions. Prof. Paul Parren, Ph.D.: Contributed to nine FDA/EMA-approved therapeutic antibodies. Inventor of DuoBody®, HexaBody®, and Gammabody technologies with 360+ issued patents. Professor at Leiden University Medical Center.   More details here: https://lnkd.in/eQ9C7uPZ   #Byondis #ScientificAdvisoryBoard #SAB #AntibodyDrugConjugate #ADCs #OncologyResearch #Oncology #Byondis #MakeHopeReal

AACR 2026 in San Diego was a great event — packed sessions, sharp science, and insightful conversations about where the ADC field is heading. And one thing is clear: differentiation matters more than ever. We are moving beyond crowded payload classes, toward distinct mechanisms, better selectivity, and smarter approaches to resistance. That is exactly the space Byondis is building in, with our cytotoxic antifolate and ByonBoost™ immune-stimulatory linker-drug platforms, and our ByonGuard™ masking technology for conditional activation. If AACR sparked a conversation you'd like to continue — on our platforms, our pipeline, or partnering — we'd love to hear from you. Get in touch at BD@Byondis.com. #AACR2026 #ADC #AntibodyDrugConjugates #Oncology #Biotech #Partnering

Next week, our Senior Director Business Development and Licensing, Ivo Grgic, will be in Basel for Swiss Biotech Day to discuss our differentiated antibody-drug conjugate (ADC) technology platforms.   Our platforms combine proprietary, novel payloads with state-of-the-art linker and conjugation technologies and conditional activation to deliver innovative #ADC therapies that can overcome the limitations of current and next-generation #cancer treatments.   If you’re attending and would like to speak with Ivo about Byondis or how we can best help you to achieve your discovery and development goals, please reach out to BD@Byondis.com.   #ADCs #SwissBiotechDay #Partnering #Biotech 

We’re headed to Prague next week for BioEquity Europe 2026.   Our CEO Dr. Christoph Korpus, MBA’s #presentation will highlight our pioneering and differentiated antibody-drug conjugate (ADC) technology platforms, including our cytotoxic antifolate linker-drug platform, ByonBoost™ immune-stimulatory linker-drug platform, and our ByonGuard™ masking technology for conditional activation.   We hope to see you at Christoph’s presentation if you are attending #BioEquity, otherwise would love to meet to discuss our platforms and fully-integrated discovery and development capabilities. Reach out to BD@Byondis.com or connect via the partneringONE™ platform to schedule a meeting.   #ADCs #BioEquity2026 #MakeHopeReal #Partnering #Innovation #BioEquityEurope

Hear from our Project Leader Mary van Helden in a new interview with Lauren Coyle at Bioconjugate Insights (BioInsights), in which they discuss the development of immunostimulatory phosphonate antibody-drug conjugates (ADCs), linker chemistry, payload design and much more.   Mary highlights Byondis' scientific approach to our proprietary ADC platforms designed to address acquired resistance, a key challenge with current ADC treatments. She explores our immunostimulatory phosphonate ADC technology platform, its engineering rationale, and why this positions our approach for use across multiple tumor targets.   To learn more, read the full interview here: https://lnkd.in/eHUAH-sU   #Byondis #BioconjugateInsights #Innovation #AntibodyDrugConjugates #ADC #OncologyResearch #MakeHopeReal

Join our Chief Scientific Officer Wim Dokter, Phd as he presents two posters at the #AACR Annual Meeting showcasing Byondis’ proprietary antibody-drug conjugate (ADC) platforms, engineered to address acquired resistance that can develop with current ADC treatments, positioning it for use across treatment lines.   Antifolate ADCs, a novel linker-drug platform for targeted therapy with a clearly differentiated mechanism of action (abstract #: 3178/13) Session Category: Experimental and Molecular Therapeutics Session Title: Targeting Cell Surface Vulnerabilities to Overcome Therapeutic Resistance Time: 20 April, 2:00 PM – 5:00 PM PDT   Phosphonate antibody-drug conjugates, an innovative, immunostimulatory class of ADCs that drive inside-out activation of Vγ9Vδ2 T cells, enabling selective tumor cell killing (abstract #: 6921/2) Session Category: Immunology Session Title: Antibody-Drug Conjugates 2 Time: 22 April, 9:00 AM – 12:00 PM PDT   More details here: https://lnkd.in/eN4kVet2   If you will be there and would like to reach out to the Byondis team: BD@Byondis.com   #AACR26 #AntibodyDrugConjugate #ADCs #OncologyResearch #Oncology #Byondis #MakeHopeReal

Join our CEO Dr. Christoph Korpus, MBA at the American Association for Cancer Research’s #Oncology Industry Partnering Event in San Diego later this week, taking place ahead of the AACR Annual Meeting.   Now in its third year, this in-person event brings together leading #pharmaceutical and #biotechnology companies, academia and the business community with the aim of accelerating progress to #cancer treatments and cures that benefit patients globally.   Christoph will be showcasing the power of Byondis’ innovative antibody-drug conjugate (ADC) technology platforms, which combine proprietary, novel payloads with state-of-the-art linker and conjugation technologies and conditional activation. Through the rapid advancement of our most differentiated programs, alongside the pursuit of business opportunities and strategic collaborations, we are delivering on our mission to bring breakthrough solutions and a new generation of cancer therapeutics for patients.   If you will be attending the event or the AACR Annual Meeting and would like to meet Christoph and the team, reach out: BD@Byondis.com   #Byondis #AACR #Innovation #AntibodyDrugConjugates #ADC #OncologyResearch #MakeHopeReal

📣 Today we announce the appointment of Dr. Christoph Korpus, MBA as Byondis’ new Chief Executive Officer.    Since joining Byondis as Chief Business Officer last year, Christoph has been instrumental in driving our strategic transformation. With more than 15 years of experience spanning oncology R&D, global business development, and strategic partnerships, he brings both deep expertise and a comprehensive understanding of our mission and capabilities.   As CEO, Christoph will guide the advancement of our proprietary antibody-drug conjugate (ADC) technology platforms as we strive to deliver on our mission to enable a new generation of cancer therapeutics for people living with cancer. His cross-discipline expertise and patient-focused vision position Byondis for our next stage of growth.   Read the full announcement here: https://lnkd.in/e4wR4CD4   #ADC #Innovation #CEO #Leadership #Oncology #Byondis #Appointment